Current Report Filing (8-k)
2023年6月21日 - 4:00AM
Edgar (US Regulatory)
0001776932
false
0001776932
2023-06-13
2023-06-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 13, 2023
MEDMEN ENTERPRISES INC.
(Exact name of registrant as specified in its charter)
British ColumbiaA1 |
|
000-56199 |
|
98-1431779 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
8740 S Sepulveda Blvd, Suite 105, Los Angeles,
California 90045
(Address, including
zip code, of principal executive offices)
Registrant’s telephone number,
including area code (424) 330-2082
Not Applicable
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol |
|
Name of Each Exchange on Which Registered |
|
|
|
|
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 5.02 | Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
On June 13, 2023, MedMen Enterprises Inc. (the
“Company”) was notified of the resignation by Ana Bowman from her position as Chief Financial Officer of the Company, which
resignation will be effective June 29, 2023. Ms. Bowman’s resignation was not the result of any disagreement with the Company on
any matters relating to its operations, policies or practices.
On June 16, 2023, the Company issued the press
release attached as Exhibit 99.1 to this report announcing the officer resignation noted under Item 5.02 above.
| Item 9.01 | Financial Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 20, 2023 |
MEDMEN ENTERPRISES INC |
|
|
|
|
/s/ Ed Record |
|
By: |
Ed Record |
|
Its: |
Chief Executive Officer |
Medmen Enterprises (CE) (USOTC:MMNFF)
過去 株価チャート
から 5 2024 まで 6 2024
Medmen Enterprises (CE) (USOTC:MMNFF)
過去 株価チャート
から 6 2023 まで 6 2024